Acoramidis
AssetAlso AG10, ALXN2060, BAY3684938, BEYONTTRA
Kinetic stabilizer of transthyretin tetramers preventing amyloidogenesis and fibril accumulation
- Stage
- Approved
- Modality
- Small molecule
- Target
- TTR
- 13
- Indications
- 5
- Trials
- 2
- Developers
Indications
14No named disease
Approved, open.fda.gov, Nov 22, 2024
Cardiac amyloidosis
Phase 3, Recruiting, NCT06563895, clinicaltrials.gov, Oct 31, 2026
Amyloid
Phase 3, Recruiting, NCT06563895, clinicaltrials.gov, Oct 31, 2026
11 more
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials5
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.